Allarity Therapeutics Inc... (ALLR)
NASDAQ: ALLR
· Real-Time Price · USD
1.65
0.10 (6.45%)
At close: Oct 06, 2025, 3:59 PM
1.66
0.61%
After-hours: Oct 06, 2025, 06:07 PM EDT
6.45% (1D)
| Bid | 1.54 |
| Market Cap | 24.11M |
| Revenue (ttm) | 6K |
| Net Income (ttm) | -24.66M |
| EPS (ttm) | 5.75 |
| PE Ratio (ttm) | 0.29 |
| Forward PE | -1.78 |
| Analyst | Strong Buy |
| Dividends | n/a |
| Ask | 1.7 |
| Volume | 558,026 |
| Avg. Volume (20D) | 7,065,171 |
| Open | 1.54 |
| Previous Close | 1.55 |
| Day's Range | 1.54 - 1.68 |
| 52-Week Range | 0.61 - 2.35 |
| Beta | 0.22 |
| Ex-Dividend Date | n/a |
About ALLR
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ALLR
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ALLR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+51.92%
Allarity Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
2 months ago
+9.8%
Allarity Therapeutics shares are trading higher after Ascendiant Capital initiated coverage on the stock with a Buy rating and announced a price target of $9.
1 month ago · proactiveinvestors.com
Allarity Therapeutics shares pop as ovarian cancer therapy recieves FDA Fast Track DesignationAllarity Therapeutics (NASDAQ:ALLR) shares more than doubled after the pharmaceutical firm annoucned that its investigational therapy for advanced ovarian cancer, stenoparib, has received Fast Track D...